Dramatic survival benefit related to R0 resection of pancreatic adenocarcinoma in patients with tumor ≤25mm in size and ≤1 involved lymph nodes

Clinical and Translational Gastroenterology

Volumn 4, Issue , 2013, Pages

  Tummala, Pavan ^a   Howard, Todd ^b   Agarwal, Banke ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MISSOURI BAPTIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PATIENT SELECTION; PERIPANCREATIC LYMPH NODE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 84886993998     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2013.4     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Benassai G, Mastrorilli M, Quarto G et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000; 73: 212-218. (Pubitemid 30238413)
3. Konstantinidis IT, Deshpande V, Zheng H et al. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma? J Gastrointest Surg 2010; 14: 261-267.
4. Sohn TA, Yeo CJ, Cameron JL et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.
5. Butturini G, Stocken DD, Wente MN et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143: 75-83. (Pubitemid 351159303)
6. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721-731.
7. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237: 74-85. (Pubitemid 36622320)
8. Moon HJ, An JY, Heo JS et al. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 2006; 32: 37-43.
9. Zacharias T, Jaeck D, Oussoultzoglou E et al. Impact of lymph node involvement on longterm survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007; 11: 350-356.
10. Massucco P, Ribero D, Sgotto E et al. Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: not just a matter of numbers. Ann Surg Oncol 2009; 16: 3323-3332.
11. Pawlik TM, Gleisner AL, Cameron JL et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141: 610-618. (Pubitemid 46616937)
12. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 2006; 13: 1189-1200. (Pubitemid 44440420)
13. Slidell MB, Chang DC, Cameron JL et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008; 15: 165-174.
14. Murakami Y, Uemura K, Sudo T et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010; 211: 196-204.
15. Kuhlmann KF, de Castro SM, Wesseling JG et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40: 549-558. (Pubitemid 38220772)
16. Winter JM, Cameron JL, Campbell KA et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10: 1199-1210.
17. Bao P, Potter D, Eisenberg DP et al. Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford) 2009; 11: 606-611.
18. Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60. (Pubitemid 47012207)
19. Breslin TM, Hess KR, Harbison DB et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123-132. (Pubitemid 32199408)
20. Arvold ND, Niemierko A, Mamon HJ et al. Pancreatic cancer tumor size on CT Scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2011; 80: 1383-1390.
21. Gress FG, Hawes RH, Savides TJ et al. Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. Gastrointest Endosc 1999; 50: 786-791.
22. Sǎ;ftoiu A, Vilmann P. Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. J Clin Ultrasound 2009; 37: 1-17.
23. Katz MH, Pisters PW, Lee JE et al. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 2011; 18: 608-610.
24. Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007; 102: 2339-2349. (Pubitemid 47493853)
25. Hartwig W, Hackert T, Hinz U et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011; 254: 311-319.